158 related articles for article (PubMed ID: 12871314)
21. In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia.
Augustsson C; Persson E
Blood; 2014 Nov; 124(20):3172-4. PubMed ID: 25232061
[TBL] [Abstract][Full Text] [Related]
22. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood.
Gerotziafas GT; Depasse F; Chakroun T; Samama MM; Elalamy I
Thromb Haemost; 2004 Mar; 91(3):531-7. PubMed ID: 14983229
[TBL] [Abstract][Full Text] [Related]
23. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation.
Lisman T; Moschatsis S; Adelmeijer J; Nieuwenhuis HK; De Groot PG
Blood; 2003 Mar; 101(5):1864-70. PubMed ID: 12411291
[TBL] [Abstract][Full Text] [Related]
24. Transfusion medicine service policies for recombinant factor VIIa administration.
Goodnough LT; Lublin DM; Zhang L; Despotis G; Eby C
Transfusion; 2004 Sep; 44(9):1325-31. PubMed ID: 15318856
[TBL] [Abstract][Full Text] [Related]
25. Kinetic modeling sheds light on the mode of action of recombinant factor VIIa on thrombin generation.
Mitrophanov AY; Reifman J
Thromb Res; 2011 Oct; 128(4):381-90. PubMed ID: 21641634
[TBL] [Abstract][Full Text] [Related]
26. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation.
Hoffman M; Monroe DM; Oliver JA; Roberts HR
Blood; 1995 Sep; 86(5):1794-801. PubMed ID: 7655009
[TBL] [Abstract][Full Text] [Related]
27. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
28. The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders.
van't Veer C; Mann KG
Semin Thromb Hemost; 2000; 26(4):367-72. PubMed ID: 11092210
[TBL] [Abstract][Full Text] [Related]
29. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay.
Turecek PL; Váradi K; Keil B; Negrier C; Berntorp E; Astermark J; Bordet JC; Morfini M; Linari S; Schwarz HP
Pathophysiol Haemost Thromb; 2003; 33(1):16-22. PubMed ID: 12853708
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms.
Keshava S; Pendurthi UR; Esmon CT; Rao LVM
J Thromb Haemost; 2020 Aug; 18(8):1911-1921. PubMed ID: 32359012
[TBL] [Abstract][Full Text] [Related]
31. A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation.
Campbell RA; Fischer TH; Wolberg AS
Br J Haematol; 2007 Jul; 138(1):82-93. PubMed ID: 17555451
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa.
van 't Veer C; Golden NJ; Mann KG
Blood; 2000 Feb; 95(4):1330-5. PubMed ID: 10666207
[TBL] [Abstract][Full Text] [Related]
33. Recombinant factor VIIa: its background, development and clinical use.
Hedner U
Curr Opin Hematol; 2007 May; 14(3):225-9. PubMed ID: 17414211
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of action, development and clinical experience of recombinant FVIIa.
Hedner U
J Biotechnol; 2006 Aug; 124(4):747-57. PubMed ID: 16697480
[TBL] [Abstract][Full Text] [Related]
35. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats.
Lauritzen B; Tranholm M; Ezban M
J Thromb Haemost; 2009 Apr; 7(4):651-7. PubMed ID: 19175492
[TBL] [Abstract][Full Text] [Related]
36. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia.
Allen GA; Hoffman M; Roberts HR; Monroe DM
Br J Haematol; 2006 Aug; 134(3):314-9. PubMed ID: 16787497
[TBL] [Abstract][Full Text] [Related]
37. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia.
Allen GA; Persson E; Campbell RA; Ezban M; Hedner U; Wolberg AS
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):683-9. PubMed ID: 17204663
[TBL] [Abstract][Full Text] [Related]
38. Variants of recombinant factor VIIa with increased intrinsic activity.
Persson E
Semin Hematol; 2004 Jan; 41(1 Suppl 1):89-92. PubMed ID: 14872428
[TBL] [Abstract][Full Text] [Related]
39. Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A.
Brophy DF; Martin EJ; Nolte ME; Kuhn JG; Barrett JC; Ezban M
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):539-46. PubMed ID: 20581663
[TBL] [Abstract][Full Text] [Related]
40. Enhanced potency of recombinant factor VIIa with increased affinity to activated platelets.
Enoksson M; Martin EJ; Holmberg H; Jensen MS; Kjelgaard-Hansen M; Egebjerg T; Buchardt J; Krogh TN; Demuth H; Sanfridson A; Hilden I; Kjalke M; Brophy DF
J Thromb Haemost; 2020 Jan; 18(1):104-113. PubMed ID: 31549480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
